[{"id":"a40d2096-ed24-41fd-89c0-83c2668d15ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT01639248","created_at":"2021-01-18T07:02:56.960Z","updated_at":"2024-07-02T16:37:20.654Z","phase":"Phase 2","brief_title":"Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC","source_id_and_acronym":"NCT01639248","lead_sponsor":"CASI Pharmaceuticals, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ENMD-2076"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2017-06-26"}]